GlaxoSmithKline submits regulatory application for UMEC/VI

A.B. | ShareCast | 18 Dec, 2012 12:05 - Updated: 12:58 | | |

needle

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD).

UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidinium bromide --- a long-acting muscarinic antagonist (LAMA)--- and vilanterol, a long-acting beta2 agonist which is administered using the Ellipta inhaler.

The application proposes the proprietary name Anora Ellipta and has been submitted to the US Food and Drug Administration for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.

Applications for UMEC/VI are also planned in the European Union and in other countries next year.

FSTE 100 company GSK is a leading research-based pharmaceutical and healthcare company.

Theravance is a biopharmaceutical company which collaborates with a number of pharmaceutical organisations.

RD

More news

20:32 Families are in desperate need of radical tax reforms, says Taxpayers' Alliance

The average UK household pays £274 more in tax than it receives in benefits, the Taxpayers’ Alliance has revealed in its latest analysis.

19:52 Theresa May launches government crackdown on international student visas

UK home secretary Theresa May has supported a plan to make international students exit the country after finishing their degree.

19:52 OPEC has no market power anymore, says former energy minister

The former energy minister of Qatar and head of OPEC has claimed that the oil cartel no longer dominates the international energy market.

18:04 Market overview: Stocks higher despite drop in Brent futures

1630:Close UK shares ended the session slightly higher, in holiday-thinned trading volumes, with few traders at their desks despite the raft of US data due out tomorrow. Precious metals miners and some commodity plays did worst as oil and gold prices headed lower. By the end of trading gold futures were to be seen down by 1.25% at $1,181 per ounce on COMEX. Over on the ICE, front month Brent crude futures dropped 1.88% to finish at $60.26 per barrel. FTSE 100 up 31 points to 6,577.

17:39 1Spatial director sells £0.5m in shares to satisfy institutional demand

Mike Sanderson, the director of strategic development of software firm 1Spatial, has raised over half a million pounds by selling shares, the company announced on Monday.

17:15 EE, Huawei, Qualcomm successfully trial next generation 4G technology

EE, together with Huawei and Qualcomm, has successfully trialled the next generation of superheats 410Mbps 4G.

17:13 Europe close: Stocks gain as Eurozone consumer confidence improves

European stocks ended higher after a report showed Eurozone consumer confidence rose more than expected in December.

17:09 London close: UK equities rise to two-week high despite weak commodity stocks

Weakness in the resource sectors limited gains in London on Monday, though equity markets still managed to register their fifth straight day of gains as investors readied themselves for the Christmas break.

16:36 Tuesday preview: UK and US third quarter GDP in focus

UK and US economic growth data for the third quarter is due for release on Tuesday.

16:34 Sector movers: Grocers fall as Tesco faces fresh inquiry

Tesco dampened the food and drug retail sector on Monday as news of a fresh investigation into the struggling supermarket chain weighed on investor confidence.